Pharma Capital
EPIC: AHZ
Market: ASX
52-week High/Low: A$0.55 / A$0.22
Sector: Pharma & Biotech
Market Cap: A$66.25M
Website: www.admedus.com

Admedus Ltd (ASX:AHZ) is a diversified healthcare company.

 

Admedus Ltd

www.admedus.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Admedus Ltd

Admedus Ltd Snapshot

Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices.

We have offices in Brisbane, Minneapolis, Zurich and Singapore and a state-of-the-art research and manufacturing facility in Malaga, Australia.

Admedus has four core divisions:

Tissue Engineering – Using our proprietary ADAPT® tissue-processing technology, we are developing a suite of regenerative bio-scaffold products designed for transformative healing in soft tissue repairs.

CardioCel® is our flagship product. It is used to repair congenital heart deformities and complex heart defects, changing patients’ lives for the better around the world. Surgeons at leading heart centres in the US, Europe, and Asia Pacific are using CardioCel® and it has been implanted in thousands of patients to date.

Sales and Distribution – Our medical products team is responsible for distributing and supporting a range of infusion solutions to hospitals in Australia and New Zealand.

Bio-manufacturing – Admedus has a state-of-the-art manufacturing facility in Australia that is used for the global production of our ADAPT suite of products as well as for R&D projects.

Immunotherapies – Working with leading immunologists, including Professor Ian Frazer and his team, we are developing next-generation vaccines for the treatment and prevention of infectious diseases and cancers with an initial focus on Herpes Simplex Virus (HSV-2) and Human papillomavirus (HPV).

www.admedus.com

Wayne Paterson
Chief Executive Officer

Wayne Paterson has held numerous senior positions in multinational pharmaceutical companies and has lived in seven countries during the past 25 years. Throughout his career, he has been responsible for building healthcare businesses around the world, including mergers/integrations/acquisitions and major restructures. He holds an MBA from the University of Southern Queensland and a degree in business studies from the Queensland University of Technology. He also studied business courses at North Western University (Kellogg School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.


David St. Denis
Chief Operating Officer

David St. Denis is an accomplished senior healthcare leader with a systematic and metrics-driven approach spanning 20 years of proven business results at the regional and global levels within the life sciences and pharmaceutical sectors. He has a Bachelor of Science from the University of Connecticut, a Masters of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College – Franklin W. Olin Graduate School of Business.


Mark Ziirsen
Chief Financial Officer

Mark is a highly-credentialed CFO and business partner with a strong track record of delivering growth and significant operational improvements across a wide variety of industries (medtech, FMCG, technology and consulting) and geographies (New Zealand, Pacific Islands, Indonesia, Sri Lanka, Hong Kong, Taiwan, Japan, South Korea, Vietnam, United States and Europe). Mark’s qualifications include a bachelor of commerce, CPA designation and an MBA majoring in international business.


Ben Jensen
Chief HR and Technology Officer

Ben is an experienced Human Resources professional with a background in manufacturing, supply chain, resources and engineering industries. His experience in business planning and change management within HR teams in North and South America, Europe, India and Asia Pacific has equipped him with broad strategic capabilities. Ben has a Business Management degree, a Masters of Employment Law and is a member of the Australian Institution of Company Directors.


Directors

John Seaberg
Chairman

Matthew Ratty
Non-Executive Director

Simon Buckingham
Non-Executive Director

 
 
 
Last updated 17th July 2017

Level 1
197 Adelaide Terrace
Perth, Western Australia, 6000

T: +61 (0)8 9266 0100
F: +61 (0)8 9266 0199

Admedus Limited
ABN 35 088 221 078

Chief Executive Officer
Wayne Paterson

Chief Operating Officer
David St Denis

Chairman
John Seaberg

Non-Executive Directors
Matthew Ratty
Simon Buckingham

Company Secretary
Maja McGuire

Patent Attorney
Winthrop and Weinstein
225 S 6th St Ste 3500, Minneapolis MN 55402 . +1 (612) 604-6400

Registered Office
26 Harris Road
Malaga, Western Australia, 6090

Telephone:    +61 8 9266 0100
Facsimile:      +61 8 9266 0199
Email: [email protected]

Share Registry
Computershare Investor Services Pty Ltd
Level 2, Reserve Bank Building
45 St Georges Terrace
Perth, Western Australia 6000
Telephone: 1300 557 010 (within Aust) +61 3 9415 4000 (outside Aust)
Facsimile: +61 3 9473 2500

Solicitors
DLA Piper
Level 31, Central Park, 152-158 St Georges Terrace
Perth, Western Australia 6000

Auditors
HLB Mann Judd
Level 4, 130 Stirling Street
Perth, Western Australia, 6000

 
 
Last updated 4th August 2017

Admedus Ltd Timeline

View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.